Global Sustained Release Ocular Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

According to APO Research, The global Sustained Release Ocular Drug Delivery Systems market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Sustained Release Ocular Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Sustained Release Ocular Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Sustained Release Ocular Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Sustained Release Ocular Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Sustained Release Ocular Drug Delivery Systems include Aciont Inc., Allergan, Envisia Therapeutics, GrayBug, Icon Bioscience, Innocore Pharmaceuticals, Neurotech Pharmaceuticals, Ocular Therapeutix and OHR Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Sustained Release Ocular Drug Delivery Systems, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Sustained Release Ocular Drug Delivery Systems, also provides the sales of main regions and countries. Of the upcoming market potential for Sustained Release Ocular Drug Delivery Systems, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Sustained Release Ocular Drug Delivery Systems sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Sustained Release Ocular Drug Delivery Systems market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Sustained Release Ocular Drug Delivery Systems sales, projected growth trends, production technology, application and end-user industry.


Sustained Release Ocular Drug Delivery Systems Segment by Company

Aciont Inc.
Allergan
Envisia Therapeutics
GrayBug
Icon Bioscience
Innocore Pharmaceuticals
Neurotech Pharmaceuticals
Ocular Therapeutix
OHR Pharmaceuticals
PolyActiva
pSivida
TheraKine
Santen Pharmaceutical

Sustained Release Ocular Drug Delivery Systems Segment by Type

Microcapsules/Nanocapsules
Microspheres/Nanosptheres
Liposome
Implants

Sustained Release Ocular Drug Delivery Systems Segment by Application

Glaucoma
Corneal Transplantation
Cataract
Others

Sustained Release Ocular Drug Delivery Systems Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Ocular Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Ocular Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Ocular Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Sustained Release Ocular Drug Delivery Systems market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sustained Release Ocular Drug Delivery Systems manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Sustained Release Ocular Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Sustained Release Ocular Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Sustained Release Ocular Drug Delivery Systems Market Size, 2020 VS 2024 VS 2031
1.3 Global Sustained Release Ocular Drug Delivery Systems Market Size Estimates and Forecasts (2020-2031)
1.4 Global Sustained Release Ocular Drug Delivery Systems Sales Estimates and Forecasts (2020-2031)
1.5 Global Sustained Release Ocular Drug Delivery Systems Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Sustained Release Ocular Drug Delivery Systems Market Dynamics
2.1 Sustained Release Ocular Drug Delivery Systems Industry Trends
2.2 Sustained Release Ocular Drug Delivery Systems Industry Drivers
2.3 Sustained Release Ocular Drug Delivery Systems Industry Opportunities and Challenges
2.4 Sustained Release Ocular Drug Delivery Systems Industry Restraints
3 Sustained Release Ocular Drug Delivery Systems Market by Manufacturers
3.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Manufacturers (2020-2025)
3.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Manufacturers (2020-2025)
3.3 Global Sustained Release Ocular Drug Delivery Systems Average Sales Price by Manufacturers (2020-2025)
3.4 Global Sustained Release Ocular Drug Delivery Systems Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Sustained Release Ocular Drug Delivery Systems Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Sustained Release Ocular Drug Delivery Systems Manufacturers, Product Type & Application
3.7 Global Sustained Release Ocular Drug Delivery Systems Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Sustained Release Ocular Drug Delivery Systems Market CR5 and HHI
3.8.2 Global Top 5 and 10 Sustained Release Ocular Drug Delivery Systems Players Market Share by Revenue in 2024
3.8.3 2024 Sustained Release Ocular Drug Delivery Systems Tier 1, Tier 2, and Tier 3
4 Sustained Release Ocular Drug Delivery Systems Market by Type
4.1 Sustained Release Ocular Drug Delivery Systems Type Introduction
4.1.1 Microcapsules/Nanocapsules
4.1.2 Microspheres/Nanosptheres
4.1.3 Liposome
4.1.4 Implants
4.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Type
4.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2020-2031)
4.2.3 Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2020-2031)
4.3 Global Sustained Release Ocular Drug Delivery Systems Revenue by Type
4.3.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2020-2031)
4.3.3 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2020-2031)
5 Sustained Release Ocular Drug Delivery Systems Market by Application
5.1 Sustained Release Ocular Drug Delivery Systems Application Introduction
5.1.1 Glaucoma
5.1.2 Corneal Transplantation
5.1.3 Cataract
5.1.4 Others
5.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Application
5.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2020-2031)
5.2.3 Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2020-2031)
5.3 Global Sustained Release Ocular Drug Delivery Systems Revenue by Application
5.3.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2020-2031)
5.3.3 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2020-2031)
6 Global Sustained Release Ocular Drug Delivery Systems Sales by Region
6.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2020-2031)
6.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2020-2025)
6.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region
7.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region
7.1.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2020-2025)
7.1.3 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2026-2031)
7.1.4 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Sustained Release Ocular Drug Delivery Systems Revenue (2020-2031)
7.2.2 North America Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Sustained Release Ocular Drug Delivery Systems Revenue (2020-2031)
7.3.2 Europe Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Sustained Release Ocular Drug Delivery Systems Revenue (2020-2031)
7.4.2 Asia-Pacific Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Aciont Inc.
8.1.1 Aciont Inc. Comapny Information
8.1.2 Aciont Inc. Business Overview
8.1.3 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.1.5 Aciont Inc. Recent Developments
8.2 Allergan
8.2.1 Allergan Comapny Information
8.2.2 Allergan Business Overview
8.2.3 Allergan Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Allergan Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.2.5 Allergan Recent Developments
8.3 Envisia Therapeutics
8.3.1 Envisia Therapeutics Comapny Information
8.3.2 Envisia Therapeutics Business Overview
8.3.3 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.3.5 Envisia Therapeutics Recent Developments
8.4 GrayBug
8.4.1 GrayBug Comapny Information
8.4.2 GrayBug Business Overview
8.4.3 GrayBug Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 GrayBug Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.4.5 GrayBug Recent Developments
8.5 Icon Bioscience
8.5.1 Icon Bioscience Comapny Information
8.5.2 Icon Bioscience Business Overview
8.5.3 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.5.5 Icon Bioscience Recent Developments
8.6 Innocore Pharmaceuticals
8.6.1 Innocore Pharmaceuticals Comapny Information
8.6.2 Innocore Pharmaceuticals Business Overview
8.6.3 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.6.5 Innocore Pharmaceuticals Recent Developments
8.7 Neurotech Pharmaceuticals
8.7.1 Neurotech Pharmaceuticals Comapny Information
8.7.2 Neurotech Pharmaceuticals Business Overview
8.7.3 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.7.5 Neurotech Pharmaceuticals Recent Developments
8.8 Ocular Therapeutix
8.8.1 Ocular Therapeutix Comapny Information
8.8.2 Ocular Therapeutix Business Overview
8.8.3 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.8.5 Ocular Therapeutix Recent Developments
8.9 OHR Pharmaceuticals
8.9.1 OHR Pharmaceuticals Comapny Information
8.9.2 OHR Pharmaceuticals Business Overview
8.9.3 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.9.5 OHR Pharmaceuticals Recent Developments
8.10 PolyActiva
8.10.1 PolyActiva Comapny Information
8.10.2 PolyActiva Business Overview
8.10.3 PolyActiva Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 PolyActiva Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.10.5 PolyActiva Recent Developments
8.11 pSivida
8.11.1 pSivida Comapny Information
8.11.2 pSivida Business Overview
8.11.3 pSivida Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 pSivida Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.11.5 pSivida Recent Developments
8.12 TheraKine
8.12.1 TheraKine Comapny Information
8.12.2 TheraKine Business Overview
8.12.3 TheraKine Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 TheraKine Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.12.5 TheraKine Recent Developments
8.13 Santen Pharmaceutical
8.13.1 Santen Pharmaceutical Comapny Information
8.13.2 Santen Pharmaceutical Business Overview
8.13.3 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Product Portfolio
8.13.5 Santen Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Sustained Release Ocular Drug Delivery Systems Value Chain Analysis
9.1.1 Sustained Release Ocular Drug Delivery Systems Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Sustained Release Ocular Drug Delivery Systems Production Mode & Process
9.2 Sustained Release Ocular Drug Delivery Systems Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Sustained Release Ocular Drug Delivery Systems Distributors
9.2.3 Sustained Release Ocular Drug Delivery Systems Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings